Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.

Blood - 1 Jun 2007

Hookham Michelle B, Elliott Joanne, Suessmuth Yvonne, Staerk Judith, Ward Alister C, Vainchenker William, Percy Melanie J, McMullin Mary Frances, Constantinescu Stefan N, Johnston James A

Abstract excerpt

The somatic JAK2 valine-to-phenylalanine (V617F) mutation has been detected in up to 90% of patients with polycythemia and in a sizeable proportion of patients with other myeloproliferative disorders such as essential thrombocythemia and idiopathic myelofibrosis. Suppressor of cytokine signaling 3 (SOCS3) is known to be a strong negative regulator of erythropoietin (EPO) signaling through interaction with both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erythropoietin
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocytes, Mononuclear

Share to Myeloproliferative Disorders

Share to Phenylalanine

Share to Suppressor of Cytokine Signaling 3 Protein

Share to Suppressor of Cytokine Signaling Proteins

Share to Valine

Source

Identifiers

PMID: 17317861
DOI: 10.1182/blood-2006-08-039735

Genes

JAK2
SOCS3
EPO
EPOR
SOCS1
SOCS2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.PMID 17317861Read ↗

A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses.Semantic proximity Read ↗

SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.Semantic proximity Read ↗

SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases.Semantic proximity Read ↗

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.Semantic proximity Read ↗

Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.Semantic proximity Read ↗

Dissociating STAT4 and STAT5 Signaling Inhibitory Functions of SOCS3: Effects on CD8 T Cell Responses.Semantic proximity Read ↗

SOCS3 is essential in the regulation of fetal liver erythropoiesis.Semantic proximity Read ↗

SOCS3Semantic proximity Read ↗

Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F.Semantic proximity Read ↗

Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras.Semantic proximity Read ↗

JAK/STAT signal transduction: regulators and implication in hematological malignancies.Semantic proximity Read ↗

Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.